DDInter122 DDInter994
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly involved in motor control. Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease. This drug was first approved in Japan on 25 March 2013. Istradefylline was granted FDA approval on 27 August 2019.
Istradefylline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Istradefylline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Istradefylline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Istradefylline {u} may lead to a major life threatening interaction when taken with {v} Apalutamide
Istradefylline {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Istradefylline may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Istradefylline may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Istradefylline may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Istradefylline may lead to a major life threatening interaction when taken with Apalutamide
Istradefylline may lead to a major life threatening interaction when taken with Idelalisib